Autophagy modulation in bladder cancer development and treatment (Review)

Li,Faping; Guo,Hui; Yang,Yuxuan; Feng,Mingliang; Liu,Bin; Ren,Xiang; Zhou,Honglan

doi:10.3892/or.2019.7286

Autophagy modulation in bladder cancer development and treatment (Review)

Authors:
- Faping Li
- Hui Guo
- Yuxuan Yang
- Mingliang Feng
- Bin Liu
- Xiang Ren
- Honglan Zhou
View Affiliations

Affiliations: Department of Urology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: August 21, 2019 https://doi.org/10.3892/or.2019.7286
Pages: 1647-1655
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bladder cancer (BC) is a potentially life‑threatening malignancy. Due to a high recurrence rate, frequent surveillance strategies and intravesical drug therapies, BC is considered one of the most expensive tumors to treat. As a fundamental evolutionary catabolic process, autophagy plays an important role in the maintenance of cellular environmental homeostasis by degrading and recycling damaged cytoplasmic components, including macromolecules and organelles. Scientific studies in the last two decades have shown that autophagy acts as a double‑edged sword with regard to the treatment of cancer. On one hand, autophagy inhibition is able to increase the sensitivity of cancer cells to treatment, a process known as protective autophagy. On the other hand, autophagy overactivation may lead to cell death, referred to as autophagic cell death, similar to apoptosis. Therefore, it is essential to identify the role of autophagy in cancer cells in order to develop novel therapeutic agents. In addition, autophagy may potentially become a novel therapeutic target in human diseases. In this review, the current knowledge on autophagy modulation in BC development and treatment is summarized.

View Figures

View References

1	Perlis N, Krahn MD, Boehme KE, Alibhai SMH, Jamal M, Finelli A, Sridhar SS, Chung P, Gandhi R, Jones J, et al: The bladder utility symptom scale: A novel patient reported outcome instrument for bladder cancer. J Urol. 200:283–291. 2018. View Article : Google Scholar : PubMed/NCBI
2	Steurer S, Singer JM, Rink M, Chun F, Dahlem R, Simon R, Burandt E, Stahl P, Terracciano L, Schlomm T, et al: MALDI imaging-based identification of prognostically relevant signals in bladder cancer using large-scale tissue microarrays. Urol Oncol. 32:1225–1233. 2014. View Article : Google Scholar : PubMed/NCBI
3	Johnson DC, Greene PS and Nielsen ME: Surgical advances in bladder cancer: At what cost? Urol Clin North Am. 42:235–252. 2015. View Article : Google Scholar : PubMed/NCBI
4	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
5	Chen C, Hu L, Chen Y and Hou J: The prognostic value of histological subtype in patients with metastatic bladder cancer. Oncotarget. 8:28408–28417. 2017.PubMed/NCBI
6	Chandrasekar T and Evans CP: Autophagy and urothelial carcinoma of the bladder: A review. Investig Clin Urol. 57 (Suppl 1):S89–S97. 2016. View Article : Google Scholar : PubMed/NCBI
7	Kelly JD, Tan WS, Porta N, Mostafid H, Huddart R, Protheroe A, Bogle R, Blazeby J, Palmer A, Cresswell J, et al: BOXIT-A randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder (CRUK/07/004). Eur Urol. 75:593–601. 2019. View Article : Google Scholar : PubMed/NCBI
8	Tan WS, Tan WP, Tan MY, Khetrapal P, Dong L, deWinter P, Feber A and Kelly JD: Novel urinary biomarkers for the detection of bladder cancer: A systematic review. Cancer Treat Rev. 69:39–52. 2018. View Article : Google Scholar : PubMed/NCBI
9	Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, Kirkels WJ, Silva FC, Oosterlinck W, Prescott S, et al: EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus calmette-guérin. Eur Urol. 69:60–69. 2016. View Article : Google Scholar : PubMed/NCBI
10	Anderson B: Bladder cancer: Overview and management. Part 2: Muscle-invasive and metastatic bladder cancer. Br J Nurs. 27:S8–S20. 2018. View Article : Google Scholar : PubMed/NCBI
11	Anderson B: Bladder cancer: Overview and disease management. Part 1: Non-muscle-invasive bladder cancer. Br J Nurs. 27:S27–S37. 2018. View Article : Google Scholar : PubMed/NCBI
12	Galluzzi L and Green DR: Autophagy-independent functions of the autophagy machinery. Cell. 177:1682–1699. 2019. View Article : Google Scholar : PubMed/NCBI
13	Dower CM, Wills CA, Frisch SM and Wang HG: Mechanisms and context underlying the role of autophagy in cancer metastasis. Autophagy. 14:1110–1128. 2018. View Article : Google Scholar : PubMed/NCBI
14	Long M and McWilliams TG: Monitoring autophagy in cancer: From bench to bedside. Semin Cancer Biol. Jul 15–2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
15	Zachari M, Gudmundsson SR, Li Z, Manifava M, Shah R, Smith M, Stronge J, Karanasios E, Piunti C, Kishi-Itakura C, et al: Selective autophagy of mitochondria on a ubiquitin-endoplasmic-reticulum platform. Dev Cell. 2019. View Article : Google Scholar : PubMed/NCBI
16	Apel A, Herr I, Schwarz H, Rodemann HP and Mayer A: Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res. 68:1485–1494. 2008. View Article : Google Scholar : PubMed/NCBI
17	Cheng Y, Ren X, Hait WN and Yang JM: Therapeutic targeting of autophagy in disease: Biology and pharmacology. Pharmacol Rev. 65:1162–1197. 2013. View Article : Google Scholar : PubMed/NCBI
18	Bishop E and Bradshaw TD: Autophagy modulation: A prudent approach in cancer treatment? Cancer Chemother Pharmacol. 82:913–922. 2018. View Article : Google Scholar : PubMed/NCBI
19	Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye WC, Zhang DM and Chen ZS: Autophagy and multidrug resistance in cancer. Chin J Cancer. 36:522017. View Article : Google Scholar : PubMed/NCBI
20	Mizumura K, Cloonan S, Choi ME, Hashimoto S, Nakahira K, Ryter SW and Choi AM: Autophagy: Friend or foe in lung disease? Ann Am Thorac Soc. 13 (Suppl 1):S40–S47. 2016.PubMed/NCBI
21	Jang M, Park R, Kim H, Namkoong S, Jo D, Huh YH, Jang IS, Lee JI and Park J: AMPK contributes to autophagosome maturation and lysosomal fusion. Sci Rep. 8:126372018. View Article : Google Scholar : PubMed/NCBI
22	Mukherjee A, Patel B, Koga H, Cuervo AM and Jenny A: Selective endosomal microautophagy is starvation-inducible in Drosophila. Autophagy. 12:1984–1999. 2016. View Article : Google Scholar : PubMed/NCBI
23	Marinković M, Šprung M, Buljubašić M and Novak I: Autophagy modulation in cancer: Current knowledge on action and therapy. Oxid Med Cell Longev. 2018:80238212018. View Article : Google Scholar : PubMed/NCBI
24	Galluzzi L, Baehrecke EH, Ballabio A, Boya P, Bravo-San Pedro JM, Cecconi F, Choi AM, Chu CT, Codogno P, Colombo MI, et al: Molecular definitions of autophagy and related processes. EMBO J. 36:1811–1836. 2017. View Article : Google Scholar : PubMed/NCBI
25	Taylor MA, Das BC and Ray SK: Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma. Apoptosis. 23:563–575. 2018. View Article : Google Scholar : PubMed/NCBI
26	Kang S, Shin KD, Kim JH and Chung T: Autophagy-related (ATG) 11, ATG9 and the phosphatidylinositol 3-kinase control ATG2-mediated formation of autophagosomes in Arabidopsis. Plant Cell Rep. 37:653–664. 2018. View Article : Google Scholar : PubMed/NCBI
27	Vicencio JM, Ortiz C, Criollo A, Jones AW, Kepp O, Galluzzi L, Joza N, Vitale I, Morselli E, Tailler M, et al: The inositol 1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1. Cell Death Differ. 16:1006–1017. 2009. View Article : Google Scholar : PubMed/NCBI
28	Feng Y, He D, Yao Z and Klionsky DJ: The machinery of macroautophagy. Cell Res. 24:24–41. 2014. View Article : Google Scholar : PubMed/NCBI
29	Döring T, Zeyen L, Bartusch C and Prange R: Hepatitis B virus subverts the autophagy elongation complex Atg5-12/16L1 and does not require Atg8/LC3 lipidation for viral maturation. J Virol. 92:2018. View Article : Google Scholar
30	Zaffagnini G, Savova A, Danieli A, Romanov J, Tremel S, Ebner M, Peterbauer T, Sztacho M, Trapannone R, Tarafder AK, et al: Phasing out the bad-How SQSTM1/p62 sequesters ubiquitinated proteins for degradation by autophagy. Autophagy. 14:1280–1282. 2018. View Article : Google Scholar : PubMed/NCBI
31	Cha-Molstad H, Yu JE, Feng Z, Lee SH, Kim JG, Yang P, Han B, Sung KW, Yoo YD, Hwang J, et al: p62/SQSTM1/Sequestosome-1 is an N-recognin of the N-end rule pathway which modulates autophagosome biogenesis. Nat Commun. 8:1022017. View Article : Google Scholar : PubMed/NCBI
32	Kwon DH, Park OH, Kim L, Jung YO, Park Y, Jeong H, Hyun J, Kim YK and Song HK: Insights into degradation mechanism of N-end rule substrates by p62/SQSTM1 autophagy adapter. Nat Commun. 9:32912018. View Article : Google Scholar : PubMed/NCBI
33	Menon MB and Dhamija S: Beclin 1 phosphorylation-at the center of autophagy regulation. Front Cell Dev Biol. 6:1372018. View Article : Google Scholar : PubMed/NCBI
34	Jung CH, Ro SH, Cao J, Otto NM and Kim DH: mTOR regulation of autophagy. FEBS Lett. 584:1287–1295. 2010. View Article : Google Scholar : PubMed/NCBI
35	Grunwald DS, Otto NM, Park JM, Song D and Kim DH: GABARAPs and LC3s have opposite roles in regulating ULK1 for autophagy induction. Autophagy. 1–15. 2019. View Article : Google Scholar : PubMed/NCBI
36	Ersahin T, Tuncbag N and Cetin-Atalay R: The PI3K/AKT/mTOR interactive pathway. Mol Biosyst. 11:1946–1954. 2015. View Article : Google Scholar : PubMed/NCBI
37	Menon S, Dibble CC, Talbott G, Hoxhaj G, Valvezan AJ, Takahashi H, Cantley LC and Manning BD: Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell. 156:771–785. 2014. View Article : Google Scholar : PubMed/NCBI
38	Dite TA, Ling NXY, Scott JW, Hoque A, Galic S, Parker BL, Ngoei KRW, Langendorf CG, O'Brien MT, Kundu M, et al: The autophagy initiator ULK1 sensitizes AMPK to allosteric drugs. Nat Commun. 8:5712017. View Article : Google Scholar : PubMed/NCBI
39	Chen W, Pan Y, Wang S, Liu Y, Chen G, Zhou L, Ni W, Wang A and Lu Y: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells. BMC Cancer. 17:342017. View Article : Google Scholar : PubMed/NCBI
40	Findlay GM, Yan L, Procter J, Mieulet V and Lamb RF: A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling. Biochem J. 403:13–20. 2007. View Article : Google Scholar : PubMed/NCBI
41	Pattingre S, Bauvy C and Codogno P: Amino acids interfere with the ERK1/2-dependent control of macroautophagy by controlling the activation of Raf-1 in human colon cancer HT-29 cells. J Biol Chem. 278:16667–16674. 2003. View Article : Google Scholar : PubMed/NCBI
42	Prick T, Thumm M, Köhrer K, Häussinger D and Vom Dahl S: In yeast, loss of Hog1 leads to osmosensitivity of autophagy. Biochem J. 394:153–161. 2006. View Article : Google Scholar : PubMed/NCBI
43	Kawauchi K, Araki K, Tobiume K and Tanaka N: p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol. 10:611–618. 2008. View Article : Google Scholar : PubMed/NCBI
44	Goldstein I, Yizhak K, Madar S, Goldfinger N, Ruppin E and Rotter V: p53 promotes the expression of gluconeogenesis-related genes and enhances hepatic glucose production. Cancer Metab. 1:92013. View Article : Google Scholar : PubMed/NCBI
45	Itahana Y and Itahana K: Emerging roles of p53 family members in glucose metabolism. Int J Mol Sci. 19:2018.PubMed/NCBI
46	Feng Z, Zhang H, Levine AJ and Jin S: The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA. 102:8204–8209. 2005. View Article : Google Scholar : PubMed/NCBI
47	Dando I, Cordani M and Donadelli M: Mutant p53 and mTOR/PKM2 regulation in cancer cells. IUBMB Life. 68:722–726. 2016. View Article : Google Scholar : PubMed/NCBI
48	Budanov AV and Karin M: p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell. 134:451–460. 2008. View Article : Google Scholar : PubMed/NCBI
49	Crighton D, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR, Gasco M, Garrone O, Crook T and Ryan KM: DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell. 126:121–134. 2006. View Article : Google Scholar : PubMed/NCBI
50	Qian X, Li X, Cai Q, Zhang C, Yu Q, Jiang Y, Lee JH, Hawke D, Wang Y, Xia Y, et al: Phosphoglycerate kinase 1 phosphorylates Beclin1 to induce autophagy. Mol Cell. 65:917.e6–931.e6. 2017. View Article : Google Scholar
51	Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD and Levine B: Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 122:927–939. 2005. View Article : Google Scholar : PubMed/NCBI
52	Zhu J, Tian Z, Li Y, Hua X, Zhang D, Li J, Jin H, Xu J, Chen W, Niu B, et al: ATG7 promotes bladder cancer invasion via autophagy-mediated increased ARHGDIB mRNA stability. Adv Sci (Weinh). 6:18019272019. View Article : Google Scholar : PubMed/NCBI
53	Wang F, Tang J, Li P, Si S, Yu H, Yang X, Tao J, Lv Q, Gu M, Yang H and Wang Z: Chloroquine enhances the radiosensitivity of bladder cancer cells by inhibiting autophagy and activating apoptosis. Cell Physiol Biochem. 45:54–66. 2018. View Article : Google Scholar : PubMed/NCBI
54	Piya S, Andreeff M and Borthakur G: Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia. Autophagy. 13:214–215. 2017. View Article : Google Scholar : PubMed/NCBI
55	Schlütermann D, Skowron MA, Berleth N, Böhler P, Deitersen J, Stuhldreier F, Wallot-Hieke N, Wu W, Peter C, Hoffmann MJ, et al: Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex. Urol Oncol. 36:160.e1–160.e13. 2018. View Article : Google Scholar
56	Chiao MT, Cheng WY, Yang YC, Shen CC and Ko JL: Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells. Autophagy. 9:1509–1526. 2013. View Article : Google Scholar : PubMed/NCBI
57	Santoni M, Amantini C, Morelli MB, Liberati S, Farfariello V, Nabissi M, Bonfili L, Eleuteri AM, Mozzicafreddo M, Burattini L, et al: Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. Br J Cancer. 109:1040–1050. 2013. View Article : Google Scholar : PubMed/NCBI
58	Hua X, Xu J, Deng X, Xu J, Li J, Zhu DQ, Zhu J, Jin H, Tian Z, Huang H, et al: New compound ChlA-F induces autophagy-dependent anti-cancer effect via upregulating Sestrin-2 in human bladder cancer. Cancer Lett. 436:38–51. 2018. View Article : Google Scholar : PubMed/NCBI
59	Li T, Xu K and Liu Y: Anticancer effect of salidroside reduces viability through autophagy/PI3K/Akt and MMP-9 signaling pathways in human bladder cancer cells. Oncol Lett. 16:3162–3168. 2018.PubMed/NCBI
60	Kou B, Liu W, Xu X, Yang Y, Yi Q, Guo F, Li J, Zhou J and Kou Q: Autophagy induction enhances tetrandrine-induced apoptosis via the AMPK/mTOR pathway in human bladder cancer cells. Oncol Rep. 38:3137–3143. 2017. View Article : Google Scholar : PubMed/NCBI
61	Alfred Witjes J, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, Hernández V, Espinós EL, Dunn J, Rouanne M, et al: Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 71:462–475. 2017. View Article : Google Scholar : PubMed/NCBI
62	Jamal-Hanjani M, Quezada SA, Larkin J and Swanton C: Translational implications of tumor heterogeneity. Clin Cancer Res. 21:1258–1266. 2015. View Article : Google Scholar : PubMed/NCBI
63	Sun Y: Tumor microenvironment and cancer therapy resistance. Cancer Lett. 380:205–215. 2016. View Article : Google Scholar : PubMed/NCBI
64	Carnero A, Garcia-Mayea Y, Mir C, Lorente J, Rubio IT and LLeonart ME: The cancer stem-cell signaling network and resistance to therapy. Cancer Treat Rev. 49:25–36. 2016. View Article : Google Scholar : PubMed/NCBI
65	Sharif T, Martell E, Dai C, Kennedy BE, Murphy P, Clements DR, Kim Y, Lee PW and Gujar SA: Autophagic homeostasis is required for the pluripotency of cancer stem cells. Autophagy. 13:264–284. 2017. View Article : Google Scholar : PubMed/NCBI
66	Lin JF, Lin YC, Tsai TF, Chen HE, Chou KY and Hwang TI: Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells. Drug Des Devel Ther. 11:1517–1533. 2017. View Article : Google Scholar : PubMed/NCBI
67	Fan B, Zhang X, Ma Y and Zhang A: Fangchinoline induces apoptosis, autophagy and energetic impairment in bladder cancer. Cell Physiol Biochem. 43:1003–1011. 2017. View Article : Google Scholar : PubMed/NCBI
68	Kang M, Lee KH, Lee HS, Jeong CW, Kwak C, Kim HH and Ku JH: Concurrent autophagy inhibition overcomes the resistance of epidermal growth factor receptor tyrosine kinase inhibitors in human bladder cancer cells. Int J Mol Sci. 18:2017. View Article : Google Scholar
69	Pan XW, Li L, Huang Y, Huang H, Xu DF, Gao Y, Chen L, Ren JZ, Cao JW, Hong Y and Cui XG: Icaritin acts synergistically with epirubicin to suppress bladder cancer growth through inhibition of autophagy. Oncol Rep. 35:334–342. 2016. View Article : Google Scholar : PubMed/NCBI
70	Dyshlovoy SA, Madanchi R, Hauschild J, Otte K, Alsdorf WH, Schumacher U, Kalinin VI, Silchenko AS, Avilov SA, Honecker F, et al: The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells. BMC Cancer. 17:932017. View Article : Google Scholar : PubMed/NCBI
71	Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema KJ, Coppes RP, Engedal N, Mari M and Reggiori F: Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 14:1435–1455. 2018. View Article : Google Scholar : PubMed/NCBI
72	Thorpe LM, Yuzugullu H and Zhao JJ: PI3K in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 15:7–24. 2015. View Article : Google Scholar : PubMed/NCBI
73	Yu X, Long YC and Shen HM: Differential regulatory functions of three classes of phosphatidylinositol and phosphoinositide 3-kinases in autophagy. Autophagy. 11:1711–1728. 2015. View Article : Google Scholar : PubMed/NCBI
74	Gewirtz DA: The four faces of autophagy: Implications for cancer therapy. Cancer Res. 74:647–651. 2014. View Article : Google Scholar : PubMed/NCBI
75	Wang X, Liu Y, Liu W, Zhang Y, Guo F, Zhang L, Cui M, Liu S and Wu R: Ubenimex, an APN inhibitor, could serve as an anti-tumor drug in RT112 and 5637 cells by operating in an Akt-associated manner. Mol Med Rep. 17:4531–4539. 2018.PubMed/NCBI
76	Amin SA, Adhikari N and Jha T: Design of aminopeptidase N inhibitors as anti-cancer agents. J Med Chem. 61:6468–6490. 2018. View Article : Google Scholar : PubMed/NCBI
77	Torrens-Spence MP, Pluskal T, Li FS, Carballo V and Weng JK: Complete pathway elucidation and heterologous reconstitution of rhodiola salidroside biosynthesis. Mol Plant. 11:205–217. 2018. View Article : Google Scholar : PubMed/NCBI